Postmyocardial infarction re-entrant ventricular arrhythmias in conscious dogs: suppression by bretylium tosylate.
作者信息
Patterson E, Gibson J K, Lucchesi B R
出版信息
J Pharmacol Exp Ther. 1981 Mar;216(3):453-8.
PMID:7205624
Abstract
摘要
相似文献
1
Postmyocardial infarction re-entrant ventricular arrhythmias in conscious dogs: suppression by bretylium tosylate.
J Pharmacol Exp Ther. 1981 Mar;216(3):453-8.
2
Electrophysiological effects of bretylium tosylate on subendocardial Purkinje fibers from infarcted canine hearts.
J Pharmacol Exp Ther. 1978 Jan;204(1):159-74.
3
Experimental and clinical pharmacology of bretylium tosylate in acute myocardial infarction: a 15-year journey.
J Pharmacol. 1986 Jul-Sep;17(3):223-43.
4
Bretylium tosylate: profile of the only available class III antiarrhythmic agent.
Clin Ther. 1985;7(2):205-24.
5
Electrophysiologic effects of bretylium tosylate on the heart.
J Pharmacol Exp Ther. 1972 Nov;183(2):264-74.
6
[Study of the electrophysiological properties of bretylium tosylate in man].
Arch Mal Coeur Vaiss. 1976 May;69(5):503-11.
7
[The effect of bretylium tosylat on the human atrio-ventricular and intraventricular conduction].
Boll Soc Ital Cardiol. 1976;21(4):601-8.
8
[Bretylium tosylate in the treatment and prevention of ventricular arrhythmia: a new look at an old drug].
Pol Tyg Lek. 1988 Oct 31;43(44):1415-8.
9
Usefulness of prophylactic bretylium in preventing ventricular fibrillation complication acute myocardial infarction.
Heart Lung. 1980 Sep-Oct;9(5):910-1.
10
Ischemia-induced conduction delay and ventricular arrhythmias: comparative electropharmacology of bethanidine sulfate and bretylium tosylate.
J Cardiovasc Pharmacol. 1989 Mar;13(3):471-82. doi: 10.1097/00005344-198903000-00017.
引用本文的文献
1
Clinical pharmacokinetics of bretylium.
Clin Pharmacokinet. 1985 May-Jun;10(3):248-56. doi: 10.2165/00003088-198510030-00004.
Zotero 插件